Abstract
The objectives of this study were to determine the cause of the crystallization in a large volume creatine supplement solution made from effervescent powders containing di-creatine citrate, and to characterize these crystals using thermal analyses and x-ray diffractometry. Creatine effervescent powders were dissolved in deionized water (pH 6.2) and stored both at room temperature (RT) (25°C) and refrigerated condition (4°C) over a period of 45 days. Creatine concentration was determined using high-performance liquid chromatography (HPLC). Intrinsic dissolution and saturated solubility of creatine, creatine monohydrate, and di-creatine citrate in water were determined and compared. Crystal growth was detected only in the refrigerated samples on the seventh day of storage. Differential Scanning Calorimetry (DSC) and x-ray diffraction (XRD) studies revealed that the crystals formed were of creatine monohydrate. Ninety percent creatine degradation was observed within 45 days for RT samples. However, at refrigerated condition this degradation was 80% within the same time period. The pH of the RT samples also increased from 3.6 to 4.5 during storage. No such increase was observed in the case of refrigerated samples. The intrinsic dissolution rate constants of the compounds decreased in the following order: dicreatine citrate>creatine>creatine monohydrate. In conclusion, di-creatine citrate used in effervescent formulation dissociates to creatine in aqueous solution and eventually crystallizes out as creatine monohydrate. Significant decrease in solubility and effect of pH contribute to this crystallization process.
This is a preview of subscription content,
to check access.References
Green AL, Simpson EJ, Littlewood JJ, Macdonald IA, Greenhaff PL. Carbohydrate ingestion augments creatine retention during creatine feeding in humans. Acta Physiol Scand. 1996;158:195–202.
Volek JS, Kraemer WJ. Creatine supplementation: its effect on human muscular performance and body composition. J Strength Cond Res. 1996;10:200–210.
Persky AM, Brazeau GA. Clinical pharmacology of the dietary supplement creatine monohydrate. Pharmacol Rev. 2001;53:161–176.
Willot CA, Young ME, Leighton B, et al. Creatine uptake in isolated soleus muscle: kinetics and dependence on sodium, but not on insulin. Acta Physiol Scand. 1999;166:99–104.
Dash AK, Miller DW, Huai-Yan H, Camazzo J, Stout Jr.: Evaluation of creatine transport using Caco-2 monolayers as an in vitro model for intestinal absorption. J Pharm Sci. 2001;90:1593–1598.
Budavari S, O Neil MJ, Smith A, Heckelman PE, eds. The Merck Index. 1 th ed. Rathway, NJ: Merck & Co, Inc; 1989:402–403.
Creatine Edge and Creatine Clear [package insert]. Omaha, NE: FSI Nutrition. US patent 5,925,378. July 20, 1999.
Edgar G, Shiver HE. The equilibrium between creatine and creatinine, in aqueous solutions: the effect of hydrogen ion. J Am Chem Soc. 1925;47:1179–1188.
Cannan RK, Shore A: The creatine-creatinine equilibrium: the apparent dissociation constants of creatine and creatinine. Biochemistry. 1928;22:920–929.
Dash AK, Mo Y, Pyne A. Solid-state properties of creatine monohydrate. J Pharm Sci. 2002;91:708–718.
Dash AK, Sawhney A. A simple LC method with UV detection for the analysis of creatine and creatinine and its application to several creatine formulations. J Pharm Biomed Anal. 2002;29:939–945.
Wood J, Syarto J, Letterman H. Improved holder for intrinsic dissolution rate studies. J Pharm Sci. 1965;54:1068.
Martin A. Physical Pharmacy. 4th ed. Philadelphia, PA: Lea & Febiger. 1993:212–250.
Grant DJW, Brittain HG: Solubility of pharmaceutical solids. In: Brittain HG, ed. Physical Characterization of Pharmaceutical Solids. New York, NY: Marcell Dekker, Inc.; 1995;321–386.
Ganguly S, Carnazzo J, Dash AK. Evaluation of the solution stability of creatine in large volume supplements [abstract]. AAPS PharmSci. 2002;4:R-6248.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ganguly, S., Jayappa, S. & Dash, A.K. Evaluation of the stability of creatine in solution prepared from effervescent creatine formulations. AAPS PharmSciTech 4, 25 (2003). https://doi.org/10.1208/pt040225
Received:
Accepted:
DOI: https://doi.org/10.1208/pt040225